NasdaqGS:MRNABiotechs
Moderna (MRNA) Stock Looks Above Fair Value After Cancer Trial News
Moderna stock has delivered a strong 84.8% return year to date, yet its low valuation score and expensive market multiples raise questions about how much of the story is already in the price.
The 84.8% gain year to date signals that investors have sharply repriced Moderna as expectations around its pipeline and future revenue have shifted.
Progress in areas such as the mRNA-4200 cancer program and the pending FDA decision on the mRNA-1010 flu vaccine can support growth hopes. At the same...